Funding News

Redcliffe Labs Has Acquired Megavision Diagnostics in Pune for ~₹40 Crore — Building the Integrated Pathology-Plus-Imaging Diagnostics Network Its ₹700 Crore FY27 Target Requires

By Mustafa Shariff, Editor In Chief · August 14,2026 · 2 min read

Mustafa Shariff, Editor In Chief — Redcliffe Labs Has Acquired Megavision Diagnostics in Pune for ~₹40 Crore — Building the Integrated Pathology-Plus-Imaging Diagnostics Network Its ₹700 Crore FY27 Target Requires

Summary

  • Redcliffe Labs Acquires Megavision Diagnostics Pune for ₹40 Crore — Building Integrated Pathology-Plus-Imaging Network Toward ₹700 Crore FY27 Revenue
  • Redcliffe Labs acquired Pune-based Megavision Diagnostics Centre for ~₹40 crore, adding radiology infrastructure and imaging capabilities to its 3,600-test pathology network — targeting ₹700 crore FY27 revenue through organic growth and strategic acquisitions.

"Megavision Diagnostics brings experienced radiologists, established radiology infrastructure, and a loyal patient community in Pune — exactly what we need to build a genuinely integrated diagnostics offering that combines our pathology strengths with high-quality imaging services. We believe that the future of diagnostics in India is integrated: same-day pathology and radiology results, under one brand, in one visit. This acquisition accelerates that vision in one of India's fastest-growing healthcare markets."

Redcliffe Labs, one of India's fastest-growing diagnostics companies, has announced the acquisition of Megavision Diagnostics Centre — a Pune-based diagnostics provider with established radiology, imaging, and related diagnostic services — in a deal valued at approximately ₹40 crore. The transaction brings experienced radiologists, radiology infrastructure (CT, MRI, ultrasound, X-ray), and an established patient community in Pune into Redcliffe Labs' expanding national diagnostics network.
Founded in 2018, Redcliffe Labs has built its growth story around high-quality, home-collection-enabled pathology testing at competitive prices — offering more than 3,600 pathology tests alongside genetic testing panels and preventive health screening packages. The Megavision acquisition marks a strategic expansion from the pathology-focused model toward the integrated diagnostics model where a single platform delivers both pathology and radiology services to patients under a unified brand.
The Integrated Diagnostics Strategic Rationale
The diagnostics industry in India has historically been organised around two distinct segments that are clinically complementary but commercially separate: pathology (blood tests, urine tests, histopathology, molecular diagnostics — laboratory-based tests requiring samples processed in a centralised laboratory) and radiology (X-ray, ultrasound, CT, MRI — imaging-based tests requiring specialised equipment and radiologist interpretation on-site or remotely).
The emerging 'integrated diagnostics' model — pursued by Dr Lal PathLabs (with its Pathnet radiology acquisition), Metropolis Healthcare (with imaging partnerships), and now Redcliffe Labs — recognises that most patients who need diagnostic testing need both pathology and imaging at the same episode of care. Offering both under one brand, at one visit, with a single prescription and a single report reduces the patient journey complexity and creates commercial advantages through cross-referral, shared patient registration, and integrated reporting.
For Redcliffe Labs, Megavision Diagnostics brings the radiology infrastructure and the trained radiologist team that a pure-play pathology company cannot build quickly from scratch — enabling the integrated model through acquisition rather than organic buildout. The Pune market — one of India's fastest-growing healthcare cities, with a large middle-class population and strong insurance penetration — is an appropriate geography for this integrated diagnostics expansion.
The HealthQuad Connection and the ₹700 Crore FY27 Target
Redcliffe Labs is a portfolio company of HealthQuad — the healthcare-focused venture capital firm whose Fund III first close of Rs 550 crore BHC Media covered in the July 1 edition. HealthQuad's investment in Redcliffe (made through its earlier funds) represents exactly the early-growth healthcare company investment model that Fund III will continue: a diagnostics platform with proven commercial traction, growing toward the scale where acquisition-led expansion becomes financially viable.
The ₹700 crore FY27 revenue target that Redcliffe Labs management has set represents approximately 2.5-3x the company's FY25 revenue run rate — an ambition that requires both organic growth (expanding the home collection network, adding new test categories, growing B2B hospital and corporate partnerships) and inorganic growth (acquisitions like Megavision that add new geographies, new capabilities, and new patient communities).
BHC Perspective
At Bengaluru Health Community, Redcliffe Labs' Megavision acquisition is a diagnostics M&A story that directly illustrates how India's diagnostics sector is maturing from point-solution specialists toward integrated care platforms. For BHC founders building in diagnostics technology, radiology AI, or health data platforms — Redcliffe's integrated pathology-plus-imaging strategy is the commercial model that the diagnostic chain customers of your platforms are increasingly pursuing. For BHC's HMEP cohort — the acquisitions strategy that takes a pathology company to an integrated diagnostics company is a fascinating healthcare business management case study.
Frequently Asked Questions
Q: What did Redcliffe Labs acquire?
A: Megavision Diagnostics Centre — a Pune-based diagnostics provider with radiology, CT, MRI, ultrasound, and X-ray capabilities — for approximately ₹40 crore. Brings experienced radiologists, imaging infrastructure, and established Pune patient base into Redcliffe's growing national diagnostics network.
Q: What is Redcliffe Labs?
A: Founded 2018, one of India's fastest-growing diagnostics companies offering 3,600+ pathology tests, genetic testing, and preventive health screening. HealthQuad portfolio company targeting ₹700 crore FY27 revenue through organic growth and strategic acquisitions like Megavision.
Q: What is the integrated diagnostics model?
A: A single platform delivering both pathology (laboratory tests) and radiology (imaging — CT, MRI, ultrasound, X-ray) to patients under one brand, in one visit. Emerging model pursued by Dr Lal PathLabs, Metropolis Healthcare, and Redcliffe Labs to reduce patient journey complexity and create commercial cross-referral advantages.